Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPT-514 in Refractory Lupus Nephritis and SLE
NCT06153095Phase 2Withdrawn
- Sponsor
- Lyell Immunopharma
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of IMPT-514 in systemic lupus erythematosus (SLE), lupus nephritis (LN), sponsored by Lyell Immunopharma. Planned start Feb 2024; status: withdrawn.
02
Drugs
IMPT-514
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06153095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153095.